12:00 AM
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Neulasta pegfilgrastim: Phase III data

Top-line data from a double-blind, Japanese Phase III trial in patients with malignant lymphoma showed that KRN125 met the primary endpoint of non-inferiority to filgrastim in reducing the duration of severe neutropenia, defined as a neutrophil count of <500 per uL....

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >